[go: up one dir, main page]

HUP0202367A2 - FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk Download PDF

Info

Publication number
HUP0202367A2
HUP0202367A2 HU0202367A HUP0202367A HUP0202367A2 HU P0202367 A2 HUP0202367 A2 HU P0202367A2 HU 0202367 A HU0202367 A HU 0202367A HU P0202367 A HUP0202367 A HU P0202367A HU P0202367 A2 HUP0202367 A2 HU P0202367A2
Authority
HU
Hungary
Prior art keywords
group
amino
fap
pharmaceutical compositions
groups
Prior art date
Application number
HU0202367A
Other languages
English (en)
Inventor
Raymond Armand Firestone
Pilar Garin-Chesa
Dietmar Leipert
Martin Lenter
Jürgen Mack
John Edward Park
Stefan Peters
Wolfgang J. Rettig
Leila A. Telan
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of HUP0202367A2 publication Critical patent/HUP0202367A2/hu
Publication of HUP0202367A3 publication Critical patent/HUP0202367A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

kPage=A;BrkToNext=N;>(57) A találmány tárgyát az általános képletűvegyületek - ahol R1 amino-alkanoil- vagy oligopeptidoil-csoport,amelynek amino-terminális aminocsoportjához adott esetben egy blokkolócsoport kapcsolódik; Ra és Rb a kettőjük közötti N-C csoporttal együttegy adott esetben szubsztituált és adott esetben benzo- vagyciclohexanocsoporttal kondenzált heterogyűrűt képez, amelyben egy vagykét metiléncsoportot adott esetben -NH-csoport, oxigén- vagy kénatomhelyettesít; R9 hidrogénatom, alkil-, cikloalkil-, aril- vagyheteoaril-csoport; és Cyt' egy citotoxikus vagy citosztatikus vegyületmaradéka; azzal a fenntartással, hogy a háromnál több aminosavegységettartalmazó oligopeptidoilcsoportokban a Gln-csoport közvetlenül csak aSer-től eltérő csoportokhoz kapcsolódhat - és előállításuk, továbbátumorok kezelésére szolgáló gyógyszerkészítményekben prodrugként valóalkalmazásuk képezi. Ó
HU0202367A 1999-05-14 2000-05-11 Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use HUP0202367A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13413699P 1999-05-14 1999-05-14

Publications (2)

Publication Number Publication Date
HUP0202367A2 true HUP0202367A2 (hu) 2002-11-28
HUP0202367A3 HUP0202367A3 (en) 2003-10-28

Family

ID=22461925

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202367A HUP0202367A3 (en) 1999-05-14 2000-05-11 Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use

Country Status (28)

Country Link
US (1) US6613879B1 (hu)
EP (1) EP1180116A2 (hu)
JP (1) JP3607201B2 (hu)
KR (1) KR20020030270A (hu)
CN (1) CN1213058C (hu)
AR (1) AR033792A1 (hu)
AU (1) AU777521B2 (hu)
BG (1) BG106096A (hu)
BR (1) BR0010564A (hu)
CA (1) CA2369933A1 (hu)
CO (1) CO5170516A1 (hu)
CZ (1) CZ20014097A3 (hu)
EA (1) EA005204B1 (hu)
EE (1) EE200100600A (hu)
HK (1) HK1048642B (hu)
HU (1) HUP0202367A3 (hu)
IL (1) IL145798A0 (hu)
MX (1) MXPA01011401A (hu)
MY (1) MY125939A (hu)
NO (1) NO20015536L (hu)
NZ (1) NZ516075A (hu)
PL (1) PL351680A1 (hu)
SK (1) SK16452001A3 (hu)
TW (1) TWI248444B (hu)
UA (1) UA73506C2 (hu)
WO (1) WO2000071571A2 (hu)
YU (1) YU80901A (hu)
ZA (1) ZA200109151B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12872002A3 (sk) 2000-03-15 2003-05-02 Bristol-Myers Squibb Pharma Company Cielené antineoplastické lieky a ich terapeutické použitie
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
BR0210149A (pt) * 2001-05-09 2004-06-29 Newbiotics Inc Pródrogas ativadas por deformilase de peptìdeo
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20030211979A1 (en) * 2002-01-30 2003-11-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor compounds
EP1333033A1 (en) * 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
CA2482029A1 (en) * 2002-04-18 2003-10-30 Maria V. Sergeeva Peptide deformylase activated prodrugs
AU2003233238A1 (en) * 2002-05-10 2003-11-11 Boehringer Ingelheim Pharma Gmbh And Co Kg Fap-activated anti-tumor prodrugs
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
TW200418508A (en) * 2002-11-14 2004-10-01 Newbiotics Inc Peptide deformylase activated prodrugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
JP2008545661A (ja) * 2005-05-19 2008-12-18 ジェネンテック・インコーポレーテッド 線維芽細胞活性化タンパク質阻害剤化合物および
WO2007111657A2 (en) * 2005-12-14 2007-10-04 Ludwig Institute For Cancer Research Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
WO2007087131A2 (en) * 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008005479A2 (en) * 2006-07-06 2008-01-10 University Of Wyoming Charge reversible polymers
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2010029422A1 (en) * 2008-09-12 2010-03-18 Cadila Pharmaceuticals Ltd. Novel dipeptidyl peptidase (dp-iv) compounds
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
CA2896337C (en) * 2012-12-28 2022-08-23 Life Sciences Research Partners Vzw Minimally toxic prodrugs
WO2014169697A1 (zh) * 2013-04-19 2014-10-23 暨南大学 长春碱类衍生物及其制备方法和应用
RS66369B1 (sr) * 2013-11-05 2025-01-31 Astrazeneca Ab Prolekovi nmda antagonista
EP4299134A3 (en) * 2014-06-13 2024-03-27 Bach Biosciences, LLC Fap-activated therapeutic agents, and uses related thereto
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
CN105524141B (zh) * 2015-11-12 2019-11-26 中山大学 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5047401A (en) * 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
ES2053547T3 (es) 1986-07-29 1994-08-01 Sunstar Kk Reactivo para someter a ensayo enfermedades periodontales.
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
AU708475B2 (en) 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
AU3224997A (en) 1996-05-29 1998-01-05 Prototek, Inc Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
ATE460180T1 (de) 1998-12-11 2010-03-15 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
JP2002542304A (ja) 1999-04-28 2002-12-10 ベクトレイムド インコーポレイテッド 酵素的に活性化された重合薬物接合体

Also Published As

Publication number Publication date
CN1213058C (zh) 2005-08-03
NO20015536L (no) 2002-01-10
NZ516075A (en) 2004-03-26
US6613879B1 (en) 2003-09-02
AR033792A1 (es) 2004-01-07
EP1180116A2 (en) 2002-02-20
JP2003500417A (ja) 2003-01-07
PL351680A1 (en) 2003-06-02
BR0010564A (pt) 2002-02-19
KR20020030270A (ko) 2002-04-24
BG106096A (bg) 2002-05-31
HK1048642A1 (en) 2003-04-11
WO2000071571A3 (en) 2001-09-07
WO2000071571A2 (en) 2000-11-30
CZ20014097A3 (cs) 2002-02-13
CO5170516A1 (es) 2002-06-27
CA2369933A1 (en) 2000-11-30
EA200101155A1 (ru) 2002-10-31
NO20015536D0 (no) 2001-11-13
JP3607201B2 (ja) 2005-01-05
MXPA01011401A (es) 2002-06-04
HUP0202367A3 (en) 2003-10-28
CN1374969A (zh) 2002-10-16
MY125939A (en) 2006-09-29
EE200100600A (et) 2003-02-17
UA73506C2 (en) 2005-08-15
SK16452001A3 (sk) 2002-03-05
YU80901A (sh) 2005-07-19
HK1048642B (zh) 2005-10-28
AU6559100A (en) 2000-12-12
WO2000071571A8 (en) 2002-03-07
ZA200109151B (en) 2002-12-17
EA005204B1 (ru) 2004-12-30
AU777521B2 (en) 2004-10-21
IL145798A0 (en) 2002-07-25
TWI248444B (en) 2006-02-01

Similar Documents

Publication Publication Date Title
HUP0202367A2 (hu) FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402458A2 (hu) Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
SE9902987D0 (sv) Novel compounds
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
SE0102438D0 (sv) New compounds
KR970042553A (ko) 캠프토테신 유도체
UA27100A1 (uk) Заміщеhі піроли, що мають активhість іhгібіторів протеіhкіhази с, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі і фармацевтичhа композиція
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ATE254630T1 (de) Cyclosporine
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
IL127352A (en) Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
HUP0004040A1 (hu) Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO20010995D0 (no) Cytotoksiske peptider modifisert med store eller lipofile rester
HUP0204531A2 (hu) Kiegészítő funkcionális oldallánc spacert hordozó új acil-pszeudodipeptidek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
MXPA04000577A (es) Derivados de dolastatina 10.
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
HUP0102579A2 (hu) Antiangiogén hatású peptid gyógyszervegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200503775A (en) Pharmaceutical composition and method for treating
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
HUP0002404A2 (hu) Aminosavszármazékok, hatóanyagként ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
TR199802537T2 (xx) Peptit t�revleri.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees